April 19, 2021

Grégory Resch joins the NCCR Microbiomes

We extend our warmest welcome to the newest PI of NCCR Microbiomes, Grégory Resch!

Following a PhD in Microbiology at the University of Basel, Grégory Resch pursued postdoctoral research at the Rockefeller University in New York, thanks to a Marie Curie Fellowship. He then moved back to Switzerland and the University of Lausanne, Department of Fundamental Microbiology, where he has been Lecturer since 2011 and Head of the Laboratory of Bacteriophage Research since 2017. In March 2021, Dr. Resch started a new position as Senior Lecturer at the Lausanne University Hospital (CHUV).

The research of Grégory Resch focuses on the development of new antimicrobials that spare the patient’s own microbiomes and represent promising strategies to fight against multi-drug resistant bacterial pathogens. In that context, Dr. Resch’s lab has been developing phage therapy (the treatment of bacterial infections by the administration of bacterial viruses called bacteriophages or phages) and phage-lysin therapy (the use of phage-derived peptidoglycan hydrolases as antibacterial agents). Dr. Resch’s Bacteriophage Laboratory will now continue to develop clinical phage therapies at the CHUV.

The Resch lab will strongly reinforce the expertise in phage biology within the NCCR, and we are excited about the new collaborative opportunities that open up! You can learn more about Grégory Resch’s research on his lab website.

Latest research: The multi-domain architecture of a bacteriophage endolysin enables intramolecular synergism and regulation of bacterial lysis